|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Arrieta O, Guzmán-de Alba E, Alba-López
LF, Acosta-Espinoza A, Alatorre-Alexander J, Alexander-Meza JF,
Allende-Pérez SR, Alvarado-Aguilar S, Araujo-Navarrete ME,
Argote-Greene LM, et al: National consensus of diagnosis and
treatment of non-small cell lung cancer. Rev Invest Clin. 65:(Suppl
1). S5–S84. 2013.PubMed/NCBI
|
|
4
|
Arrieta O, Ramírez-Tirado LA, Báez-Saldana
R, Peña-Curiel O, Soca-Chafre G and Macedo-Perez EO: Different
mutation profiles and clinical characteristics among Hispanic
patients with non-small cell lung cancer could explain the
‘Hispanic paradox’. Lung Cancer. 90:161–166. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
National Cancer Institute, . SEER Stat
Fact Sheets: Lung and Bronchus Cancer. Available from. http://seer.cancer.gov/statfacts/html/lungb.htmlAccessed
on April 1, 2016.
|
|
6
|
Azzoli CG, Giaccone G and Temin S:
American society of clinical oncology clinical practice guideline
update on chemotherapy for stage IV non-small-cell lung cancer. J
Oncol Pract. 6:39–43. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sun S, Schiller JH, Spinola M and Minna
JD: New molecularly targeted therapies for lung cancer. J Clin
Invest. 117:2740–2750. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Siegelin MD and Borczuk AC: Epidermal
growth factor receptor mutations in lung adenocarcinoma. Lab
Invest. 94:129–137. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gazdar AF: Epidermal growth factor
receptor inhibition in lung cancer: The evolving role of
individualized therapy. Cancer Metastasis Rev. 29:37–48. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pirker R, Pereira JR, Szczesna A, von
Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT,
Ganul V, et al: Cetuximab plus chemotherapy in patients with
advanced non-small-cell lung cancer (FLEX): An open-label
randomised phase III trial. Lancet. 373:1525–1531. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Paz-Ares L, Mezger J, Ciuleanu TE, Fischer
JR, von Pawel J, Provencio M, Kazarnowicz A, Losonczy G, de Castro
G Jr, Szczesna A, et al: Necitumumab plus pemetrexed and cisplatin
as first-line therapy in patients with stage IV non-squamous
non-small-cell lung cancer (INSPIRE): An open-label, randomised,
controlled phase 3 study. Lancet Oncol. 16:328–337. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Douillard JY, Pirker R, O'Byrne KJ, Kerr
KM, Störkel S, von Heydebreck A, Grote HJ, Celik I and Shepherd FA:
Relationship between EGFR expression, EGFR mutation status, and the
efficacy of chemotherapy plus cetuximab in FLEX study patients with
advanced non-small-cell lung cancer. J Thorac Oncol. 9:717–724.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hirsch FR, Dziadziuszko R, Thatcher N,
Mann H, Watkins C, Parums DV, Speake G, Holloway B, Bunn PA Jr and
Franklin WA: Epidermal growth factor receptor immunohistochemistry:
Comparison of antibodies and cutoff points to predict benefit from
gefitinib in a phase 3 placebo-controlled study in advanced
nonsmall-cell lung cancer. Cancer. 112:1114–1121. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
O'Byrne KJ, Gatzemeier U, Bondarenko I,
Barrios C, Eschbach C, Martens UM, Hotko Y, Kortsik C, PazAres L,
Pereira JR, et al: Molecular biomarkers in non-small-cell lung
cancer: A retrospective analysis of data from the phase 3 FLEX
study. Lancet Oncol. 12:795–805. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pirker R, Pereira JR, von Pawel J,
Krzakowski M, Ramlau R, Park K, de Marinis F, Eberhardt WE,
Paz-Ares L, Störkel S, et al: EGFR expression as a predictor of
survival for first-line chemotherapy plus cetuximab in patients
with advanced non-small-cell lung cancer: Analysis of data from the
phase 3 FLEX study. Lancet Oncol. 13:33–42. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Herbst RS and Shin DM: Monoclonal
antibodies to target epidermal growth factor receptor-positive
tumors: A new paradigm for cancer therapy. Cancer. 94:1593–1611.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Toyooka S, Mitsudomi T, Soh J, Aokage K,
Yamane M, Oto T, Kiura K and Miyoshi S: Molecular oncology of lung
cancer. Gen Thorac Cardiovasc Surg. 59:527–537. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Brugger W, Triller N, BlasinskaMorawiec M,
Curescu S, Sakalauskas R, Manikhas GM, Mazieres J, Whittom R, Ward
C, Mayne K, et al: Prospective molecular marker analyses of EGFR
and KRAS from a randomized, placebo-controlled study of erlotinib
maintenance therapy in advanced non-small-cell lung cancer. J Clin
Oncol. 29:4113–4120. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kosaka T, Yamaki E, Mogi A and Kuwano H:
Mechanisms of resistance to EGFR TKIs and development of a new
generation of drugs in non-small-cell lung cancer. J Biomed
Biotechnol. 2011:1652142011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Johnson ML, Sima CS, Chaft J, Paik PK, Pao
W, Kris MG, Ladanyi M and Riely GJ: Association of KRAS and EGFR
mutations with survival in patients with advanced lung
adenocarcinomas. Cancer. 119:356–362. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kuan FC, Kuo LT, Chen MC, Yang CT, Shi CS,
Teng D and Lee KD: Overall survival benefits of first-line EGFR
tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung
cancers: A systematic review and meta-analysis. Br J Cancer.
113:1519–1528. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Merrick DT, Kittelson J, Winterhalder R,
Kotantoulas G, Ingeberg S, Keith RL, Kennedy TC, Miller YE,
Franklin WA and Hirsch FR: Analysis of c-ErbB1/epidermal growth
factor receptor and c-ErbB2/HER-2 expression in bronchial
dysplasia: Evaluation of potential targets for chemoprevention of
lung cancer. Clin Cancer Res. 12:2281–2288. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Berghoff AS, Magerle M, IlhanMutlu A,
Dinhof C, Widhalm G, Dieckman K, Marosi C, Wohrer A, Hackl M,
Zöchbauer-Müller S, et al: Frequent overexpression of ErbB-receptor
family members in brain metastases of non-small cell lung cancer
patients. APMIS. 121:1144–1152. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hirsch FR, VarellaGarcia M, Cappuzzo F,
McCoy J, Bemis L, Xavier AC, Dziadziuszko R, Gumerlock P, Chansky
K, West H, et al: Combination of EGFR gene copy number and protein
expression predicts outcome for advanced non-small-cell lung cancer
patients treated with gefitinib. Ann Oncol. 18:752–760. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Arrieta O, SaavedraPerez D, Kuri R,
AvilesSalas A, Martinez L, MendozaPosada D, Castillo P, Astorga A,
Guzman E and De la Garza J: Brain metastasis development and poor
survival associated with carcinoembryonic antigen (CEA) level in
advanced non-small cell lung cancer: A prospective analysis. BMC
Cancer. 9:1192009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Langer CJ, Stephenson P, Thor A, Vangel M
and Johnson DH: Eastern Cooperative Oncology Group Study 2598:
Trastuzumab in the treatment of advanced non-small-cell lung
cancer: Is there a role? Focus on Eastern Cooperative Oncology
Group study 2598. J Clin Oncol. 22:1180–1187. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bradley JD, Paulus R, Komaki R, Masters G,
Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A,
et al: Standard-dose versus high-dose conformal radiotherapy with
concurrent and consolidation carboplatin plus paclitaxel with or
without cetuximab for patients with stage IIIA or IIIB
non-small-cell lung cancer (RTOG 0617): A randomised, two-by-two
factorial phase 3 study. Lancet Oncol. 16:187–199. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rüschoff J, Kerr KM, Grote HJ, Middel P,
von Heydebreck A, Alves VA, Baldus SE, Buttner R, Carvalho L, Fink
L, et al: Reproducibility of immunohistochemical scoring for
epidermal growth factor receptor expression in non-small cell lung
cancer: Round robin test. Arch Pathol Lab Med. 137:1255–1261. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Thatcher N, Hirsch FR, Luft AV, Szczesna
A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy
G, et al: Necitumumab plus gemcitabine and cisplatin versus
gemcitabine and cisplatin alone as first-line therapy in patients
with stage IV squamous non-small-cell lung cancer (SQUIRE): An
open-label, randomised, controlled phase 3 trial. Lancet Oncol.
16:763–774. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mazières J, Peters S, Lepage B, Cortot AB,
Barlesi F, BeauFaller M, Besse B, Blons H, MansuetLupo A, Urban T,
et al: Lung cancer that harbors an HER2 mutation: Epidemiologic
characteristics and therapeutic perspectives. J Clin Oncol.
31:1997–2003. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rüschoff J, Hanna W, Bilous M, Hofmann M,
Osamura RY, PenaultLlorca F, van de Vijver M and Viale G: HER2
testing in gastric cancer: A practical approach. Mod Pathol.
25:637–650. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Prenzel N, Fischer OM, Streit S, Hart S
and Ullrich A: The epidermal growth factor receptor family as a
central element for cellular signal transduction and
diversification. Endocr Relat Cancer. 8:11–31. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sun G, Liu B, He J, Zhao X and Li B:
Expression of EGFR is closely related to reduced 3-year survival
rate in Chinese female NSCLC. Med Sci Monit. 21:2225–2231. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hirsch FR, VarellaGarcia M, McCoy J, West
H, Xavier AC, Gumerlock P, Bunn PA Jr, Franklin WA, Crowley J,
Gandara DR; Southwest Oncology Group, ; et al: Increased epidermal
growth factor receptor gene copy number detected by fluorescence in
situ hybridization associates with increased sensitivity to
gefitinib in patients with bronchioloalveolar carcinoma subtypes: A
Southwest Oncology Group Study. J Clin Oncol. 23:6838–6845. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rotella V, Fornaro L, Vasile E, Tibaldi C,
Boldrini L, Chella A, D'Incecco A, Cirigliano G, Chioni A, Lupi C,
et al: EGFR and K-Ras mutations in women with lung adenocarcinoma:
Implications for treatment strategy definition. J Exp Clin Cancer
Res. 33:772014. View Article : Google Scholar : PubMed/NCBI
|
